Project Grant 2229323
- This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is focused on the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The goal is to address the critical health and economic burden associated with implant-related infections by reducing or eliminating them through the use of this biocompatible and antimicrobial nano-biological coating. The $305,000...
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- Pumpkinseed Technologies Inc. received a $353,204 Phase I Small Business Innovation Research (SBIR) Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on June 19, 2025, with completion targeted for April 30, 2026. The award funds development and proof-of-concept demonstration of Cell-MAPP (Cell Monitoring Against Presented Peptides), a novel technology that enables dynamic, real-time monitoring of individual T cell states during antigen...
- The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Cellecho, Inc. to develop a microchip-based technology for advanced cell engineering. The goal is to create a miniaturized liquid and cell handling platform that leverages acoustic-electric micro-vortices to precisely and sequentially deliver genetic molecules. This innovation aims to make complex cell reprogramming more...
- Federal Project Grant Award Summary Cellfe, Inc. received a $314,000 Phase I Small Business Innovation Research (SBIR) Project Grant from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2026. The award funds proof-of-concept research and development services to optimize the CellFE platform, a microfluidic transfection technology designed to enable same-day sequential...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Small Business Innovation Research (SBIR) Phase I project award of $274,998 to Magnify Biosciences Inc. aims to develop an automated "AutoMagnify" device that physically expands biological specimens up to 1,000 times in 3D while preserving spatial and molecular integrity. This advancement will enable conventional light microscopes to achieve nanoscale imaging resolution capabilities...
- This federal Project Grant award of $349,566 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of a Spotting-Free Nano-Oscillator Array (SFNOA) technology for high-throughput, label-free quantification of ligand binding kinetics to transmembrane proteins in their native states. The key products and services delivered through this award include: Integration of innovative technologies...
SBIR PHASE I: DEVELOPMENT OF ARRAYS TO RECORD DYNAMIC INTERACTIONS BETWEEN SINGLE CELLS -THE BROADER/COMMERCIAL IMPACT OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT IS TO ENABLE EXPERTS IN THE BIOMEDICAL FIELD TO IMPROVE UNDERSTANDING OF HOW NEW THERAPEUTIC APPROACHES ARE DEVELOPED AND PERFORM IN THE CONTEXT OF A COMPLEX IMMUNE SYSTEM. THIS TECHNOLOGY COULD ENABLE NEW THERAPIES TO TRANSLATE TO PATIENTS FASTER, AT LESS EXPENSE, AND WITH HIGHER RATES OF SUCCESS. THESE THERAPEUTICS, SUCH AS ANTIBODIES, CELL AND GENE THERAPIES, AND VACCINES, CAN DELIVER EXCELLENT RESULTS WHEN THEY WORK, BUT AVAILABLE THERAPIES DO NOT WORK FOR ALL PATIENTS. TO DEVELOP AND DELIVER THE NEXT GENERATION OF THERAPIES TO IMPROVE THE LIVES OF PATIENTS, INVESTIGATORS NEED TO BE ABLE TO UNDERSTAND HOW IMMUNE CELLS AND OTHER CELLS MOVE, INTERACT, KILL, AND SURVIVE OVER TIME. THIS PROJECT ALLOWS RESEARCHERS, DEVELOPERS, AND MANUFACTURING EXPERTS TO UNDERSTAND THE FUNCTIONAL PERFORMANCE OF NEW THERAPIES EARLIER, MORE COMPLETELY, AND AT LOWER EXPENSE. SUCH SINGLE-CELL ANALYSIS IS A MULTI-BILLION MARKET AMONG COMMERCIAL AND NON-PROFIT MARKETS. THE PROPOSED PROJECT WILL DEVELOP AND RIGOROUSLY VALIDATE A NOVEL ARRAY CONSUMABLE THAT ENABLES SCALING DYNAMIC, SINGLE-CELL ANALYSIS FROM AN EARLY ACCESS LABORATORY TO ANY FACILITY WORLDWIDE. INITIAL DESIGN AND TESTING ACTIVITIES FOR THE NEXT GENERATION ARRAYS USING NON-SCALABLE PROOF OF CONCEPT PRODUCTION METHODOLOGIES HAVE DEMONSTRATED THE VALUE OF THE DYNAMIC SINGLE-CELL FUNCTIONAL ANALYSIS PLATFORM. THIS PROJECT WILL DEVELOP AND EVALUATE TWO OPTIONS FOR PRODUCING THE ARRAYS, ONE WITH AN EMBOSSING TECHNIQUE AND ONE WITH A THREE-DIMENSIONAL PRINTING TECHNIQUE. SUCCESSFUL COMPLETION OF THIS PROJECT WILL SUPPORT SCALING THE ONLY PLATFORM THAT CAN EVALUATE MIGRATION, CONTACT DYNAMICS, KILLING, SURVIVAL, SUBCELLULAR ACTIVITY, AND BIOMOLECULE SECRETION FOR THE SAME INDIVIDUAL CELL OVER TIME AND IN HIGH THROUGHPUT TO IMPROVE DEVELOPMENT AND DELIVERY OF NOVEL THERAPIES FASTER, WITH HIGHER RATES OF SUCCESS, AND AT LOWER EXPENSE. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 11/21/24 | ||
| Not listed | $0 | 2/7/24 | ||
| Not listed | $275.0k | 5/30/23 |